Interim results for the six months ended June 30, 2024
26 sept. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an...
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
24 sept. 2024 09h15 HE
|
GT Biopharma, Inc.
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
19 sept. 2024 06h55 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
04 sept. 2024 09h25 HE
|
Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...
Receipt of Nasdaq Delisting Determination - Plans to Appeal
30 août 2024 16h30 HE
|
Biodexa Pharmaceuticals PLC
August 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused...
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
23 juil. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)...
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
22 juil. 2024 08h00 HE
|
Hepion Pharmaceuticals, Inc.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
AstriVax enters clinical phase with its novel vaccine platform technology
24 juin 2024 01h00 HE
|
AstriVax
The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with AstriVax technology. The study will also provide...
BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique
03 juin 2024 00h00 HE
|
Biophta
COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement (via le...
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
03 juin 2024 00h00 HE
|
Biophta
PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the...